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Abstract 
Purpose: To explore effects of atorvastatin in combination with probucol on blood lipid and serum C-
reactive protein of patients with cerebral infarction. 
Methods: In total, 120 patients with confirmed cerebral infarction were randomly divided into test and 
control groups (n = 60 each). Control group was given atorvastatin 20 mg, once every night, while test 
group received 0.5 g probucol twice daily plus atorvastatin 20 mg nightly. The treatment for both groups 
lasted for six months. Changes in carotid intima media thickness (CIMT), plaque area, vulnerability, 
high-sensitivity C-reactive protein level (hs-CRP) and low density lipoprotein (LDL) were observed 
before and after treatment and compared between groups. In 6-month follow up, incidence of newly 
occurred or reoccurred cerebral ischemic stroke were observed and compared between groups. 
Occurrence of severe untoward reaction was also noted.  
Results: In test group, LDL level significantly decreased after treatment, (p < 0.01), and when 
compared to control group (p < 0.05). CIMT, plaque area and number of vulnerable plaque after 
treatment were significantly different compared to the values prior to treatment and control group (p < 
0.05). Incidence of cerebral ischemic stroke was similarly lower for the test group than control after 
treatment (p < 0.05). Both groups did not develop any severe untoward reaction.  
Conclusion: Atorvastatin, in combination with probucol, can be used to regulate blood lipid, lower LDL 
level, reduce number of vulnerable plaque, stabilize and reverse plaque, and lower risk of cerebral 
ischemic stroke of carotid atherosclerostic plaque. This work provides a theoretical basis and 
intervention measure for preventing ischemic stroke. 
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Cerebral infarction with high incidence rate, 
mortality rate, recurrence rate and disability rate 
is more likely to happen in middle aged and 
elderly people; it has been the primary cause for 
long-term disability of middle aged and elderly 
people worldwide, and also the second cause 
leading to death in China [1].  
 
Carotid atherosclerostic plaque is considered as 
the primary cause of the occurrence of cerebral 
infarction [2]. Detecting the stability of carotid 
atherosclerostic plaque as soon as possible and 
using drugs that are beneficial for the stability of 
plaque are of great importance to prevent the 
occurrence of cerebral infarction clinically. In 
2014, Hao et al [3] have proved that atorvastatin 
combined with probucol does not only improve 
adiponectin level of cerebral infraction patients 
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but also lower high-sensitivity C-reactive protein 
(hs-CRP) level, which is beneficial to stabilize 
atherosclerotic plaque and control the 
occurrence of cerebral infarction. Zhang [4] 
pointed out that probucol combined with statin 
was effective in resisting inflammation and 
improving the level of adiponectin in the 
treatment of acute myocardial infarction (AMI), 
thereby protecting angiocarpy. Based on 
experiments, Gao et al [5] found that, statins 
could effectively control and lower CRP level and 
blood lipid, reduce inflammation and eliminate 
carotid atherosclerostic plaque; and atorvastatin 
could reduce carotid intima media thickness 
(CIMT) while being used in secondary 
prevention.  
 
This study used atorvastatin combined with 
probucol to treat cerebral infarction patients and 
analyzed the influence of atorvastatin combined 
with probucol on blood lipid and serum C-
reactive protein of patients with cerebral 
infarction by performing ultrasonic blood vessel 






A total of 120 patients who were verified to have 
carotid atherosclerostic plaque in First Affiliated 
Hospital of Zhengzhou University, Zhengzhou, 
China from May 2010 to April 2011 were 
selected. Of them, 50 cases had transient 
ischemic attack/minor stroke, based on National 
Institute of Health stroke scale (NIHSS) score 
criteria of < 4 points. All cases conformed to the 
diagnostic criteria of carotid artery 
atherosclerosis formulated by WHO [6]. Clinical 
symptoms, sign and diagnostic results of 
computed tomography (CT) or magnetic 
resonance imaging (MRI) of cases of transient 
ischemic attack/ minor stroke all conformed to 
the diagnostic criteria stipulated by the 4th 
Cerebrovascular Disease Conference held by 
Chinese Medical Association [7]. All participants 
signed inform consent and this study has been 
approved by the ethics committee of the First 
Affiliated Hospital of Zhengzhou University, 
Zhengzhou, China. 
 
Inclusion criteria of cerebral infarction 
 
Patients who were confirmed by CT and MRI to 
conform to the guidelines of 4th National 
Conference on the Diagnosis of Cerebrovascular 
Disease were included in the study. Also, 
patients who were confirmed to have carotid 
arteriosclerosis plaque by vascular ultrasound 
and who had CIMT on both sides or one side ≥ to 




Patients who had a large area of cerebral 
infarction, IMT less than 1.0 mm or diseases 
such as rheumatic heart disease, atrial 
fibrillation, obvious hepatic failure and liver and 





The recruited patients were randomly divided into 
test group and treatment group, 60 in each 
group. The test group comprised of 35 males and 
25 females, ranging in age from 45 ~ 76 years 
(mean, 59.3 ± 7.2 years), while control group had 
38 males and 22 females, ranging in age from 44 
to 78 years (mean, 58.6 ± 7.9 years). Differences 
in demographic characteristics between the two 
groups with regard to age, gender, weight index, 
smoking condition, drinking condition, 
hypertension and diabetes were not statistically 




Control group was given diet and living style 
improvement therapy, 20 mg atorvastatin calcium 
tablets Lipitor®, Huirui Pharmaceutical Co., Ltd, 
China) once nightly, as well as treatment for 
controlling blood pressure, blood glucose, 
smoking cessation and antiplatelet. For the 
treatment group, patients were given 0.5 g 
probucol (twice each day) plus atorvastatin (20 
mg, once nightly). Six ml venous blood was 
extracted from patients before treatment and also 
6 months after treatment to assess low density 
lipoprotein (LDL), blood lipid, high-sensitivity C-
reactive protein (hs-CRP), blood routine, liver 
renal function and creatine kinase. In addition, 
the blood vessels of the neck were examined by 
color Doppler ultrasound. LDL detection kit was 
used enzyme colorimetry (Ningbo Meikang 
Biotech Science and Technology Co., Ltd., 
China) with the aid of BecKman DXC-800 
automatic analyzer while hs-CRP was 
determined using rate scatter turbid assay and 
brain natriuretic peptide (BNP) analyzer 
(Siemens Medical Diagnosis Product Co., Ltd, 
Shanghai, China).  
 
In addition, Philips IU22 color ultrasonography 
was used to detect bilateral common carotid 
artery, carotid bulb and extracranial internal 
carotid artery. Patients were asked to fully 
expose their lateral neck by taking supine 
position with the head towards tilted to the 
Wang et al 
Trop J Pharm Res, December 2015; 14(12): 2315  
 
unexamined side. L9-3 two-dimensional linear 
probe was applied to perform whole-process 
monitoring on carotid artery, e.g., observe 
condition of intima, size, form and echo 
characteristics of plaque and degree of stenosis 
of lumen. If the site that was 1.5 cm away from 
bifurcation of common carotid artery had 
atherosclerotic plaque, then vertical distance 
between intima and interface between media 
membrane and outer membrane was measured. 





All the data were processed by SPSS 17.0. Data 
were expressed as mean ± standard deviation 
(SD). Comparison between two groups was 
performed by t test, and measurement data was 
compared by chi-square test. Difference was 




Comparison of blood fat level of two groups 
before and after treatment 
 
Blood fat level in both groups had no difference 
before treatment. In test group, total cholesterol 
(TC), low-density lipoprotein cholesterol (LDL-C) 
and triglyceride level obviously decreased (p < 
0.01), but high density lipoprotein-cholesterol 
(HDL-C) had no obvious decline (p > 0.05); in 
control group, TC, LDL and TG level showed a 
significant decrease (p < 0.01), but HDL level 
rose (p < 0.05). 
  
After treatment, test group displayed lower TC 
and LDL-C levels than control group (p < 0.05); 
TG level was not significantly different between 
the two groups (p > 0.05); control group exhibited 
increased HDL-C, but test group showed no 
remarkable increase of HDL-C (p > 0.05). Details 
are shown in Table 1. 
 
Comparison of hs-CRP level of two groups 
before and after treatment 
 
hs-CRP level in two groups was not significantly 
different before treatment (p > 0.05). After 
treatment, hs-CRP level significantly decreased 
in both groups (p < 0.01); and a remarkable 
difference was also found between test group 
and control group (p < 0.05). Details are shown 
in Table 2. 
 
Comparison of CIMT and plaque area  
 
CIMT and plaque area decreased in both groups 
after treatment and there was remarkable 
difference within group (p < 0.05), and the 
difference between two groups was also 
statistically significant (p < 0.05), as shown in 
Table 3. 
 
Comparison of reduced number of vulnerable 
plaque before and after treatment 
 
Vulnerable plaque reduced in both groups after 
treatment and there was a remarkable difference 
within group (p < 0.05), and the comparison 
between two groups after treatment also showed 
a significant difference (p < 0.05) (Table 4). 
 
 
Table 1: Comparison of blood lipid level of the two groups before and after treatment (mean ± SD, mmol/L) 
 
Item Test group Control group 
Before treatment After treatment Before treatment After treatment 
TC 5.52±1.12  4.30±1.35#△ 5.13±1.37  3.10±0.95# 
TG 2.24±0.75  1.51±0.35＃ 2.32±1.12  1.59±0.75# 
LDL-C 3.66±0.65  2.14±0.65#△ 3.75±0.51  2.74±0.42# 
HDL-C 1.27±0.31  1.07±0.28* 1.28±0.26  1.55±0.31# 
# p < 0.01, *p > 0.05 compared to pre-treatment levels; for comparison of two groups after treatment, △ indicates 
p < 0.05 
 
Table 2: Comparison of hs-CRP levels of the two groups before and after treatment (mean ± SD, mg/L) 
 
Item Test group Control group 
Before treatment After treatment Before treatment After treatment 
hs-CRP 8.03±1.12  3.10±1.3#* 8.22±1.37  4.56±1.29# 
#p < 0.01 compared to pre-treatment levels; * indicates p < 0.05 in comparison of two groups after treatment 
 
Wang et al 
Trop J Pharm Res, December 2015; 14(12): 2316  
 




(n = 60) 
 CIMT (mm)  Plaque area（mm2） 
Before treatment After treatment Before 
treatment 
After treatment 
Test group   1.07±0.37  0.92±0.24#* 0.81±0.55  0.52±0.32# 
Control group  1.05±0.39  0.98±0.26# 0.80±0.46  0.68±0.54# 
P > 0.05 for comparison of two groups before treatment; #p < 0.05 for comparison within group before and after 
treatment; *p < 0.05 for comparison between two groups post-treatment 
 




(n = 60) 
Vulnerable plaque Stable plaque 
Before treatment After treatment Before treatment After treatment 
Test group  31 (51.6)   21 (35)#*  29 (48.4)   39 (65) 
Control group  30 (50.0) 26 (43.3)# 30 (50.0)   34 (56.7)  
P > 0.05 for comparison of the two groups before treatment; #p < 0.05 for comparison before and after treatment 




In the treatment group, 3 cases had discomfort in 
upper abdomen in the 7th day after treatment, 
but were relieved after taking drugs. In control 
group, one case developed tolerable headache 
and relieved several days later. Liver function, 
renal function, blood routine and creatine kinase 
in both groups were within normal range before 




Pathophysiologic process of cerebral infarction 
can be understood as local avascular necrosis of 
brain tissue occurring to/in patients with 
atherosclerosis. Brain tissue is especially 
sensitive to ischemia and oxygen deficit. Once 
the blood supply stops for 4 to 6 min, 
unrecoverable injury is likely to occur. Thus, 
atherosclerosis is thought to be the basis of 
cerebral thrombosis, and also the most common 
factor and high risk factor of cerebral infarction 
occurrence [8].  
 
Stability of carotid atherosclerostic plaque is 
considered to be closely correlated to the 
occurrence of cerebral infarction [9]; therefore, 
treatment of atherosclerotic lesion and stable 
plaque focuses on lipid regulation, oxidation 
resistance, anti-inflammation, platelet resistance 
and improvement of endothelial function [10]. In 
atherosclerotic lesion, lipid core and fibrous cap 
constitute the mature plaque. Based on data 
from vascular ultrasound, atherosclerotic plaque 
can be divided into low echo plaque and high 
echo plaque. High echo plaque, which is featured 
by a thick fibrous cap along with small and strong 
lipid necrotic core, is not easy to break, while low 
echo plaque featured by thin fibrous cap and big 
lipid necrotic core is easy to break. Instability of 
atherosclerosis is the leading cause and also the 
independent predictive factor for cerebral 
infarction. Cerebral infarction is based on 
atherosclerosis which is a chronic inflammatory 
reaction that occurs following blood vessel 
impairment. Several inflammatory cells and 
cytokines are involved in the occurrence and 
development of atherosclerosis [11].  
 
Dyslipidemia is one of the most important risk 
factors of atherosclerosis; LDL-C can result in 
atherosclerosis, while HDL-C can resist it. A 
previous research [12] demonstrates that patient 
with dyslipidemia presents remarkably increased 
LDL-C and HDL-C. It has been found that 
inflammatory reaction plays an important role in 
the instability and disruption of atherosclerotic 
plaque. CRP, a sensitive index for detecting 
inflammatory reaction, correlates positively with 
severity of atherosclerosis, and it can be taken 
as the risk predictor of cardiovascular and 
cerebrovascular events that occur in patients 
with atherosclerosis [13].  
 
Atorvastatin, a reductase inhibitor for hydroxy-
methyl-glutaryl-CoA (HMG-CoA), is a rate-
limiting enzyme [14]. It can block endogenous 
cholesterol synthesis by inhibiting the reductase 
of HMG-CoA. Atorvastatin is able to stabilize and 
reduce plaque as it can increase the amount of 
LDL receptors on the surface of cell by induction, 
thus promoting catabiosis of LDL mediated by 
receptor. Probucol, an antioxidant certified by 
American Food and Drug Administration, plays 
the role of resisting oxidation, atherosclerosis 
and restenosis induced by angioplasty. To be 
specific, it can lower the level of ox-LDL, prevent 
or delay the occurrence and development of 
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atherosclerosis and reduce the occurrence of 
myocardial infarction and stroke through multiple 
pathways [15].  
 
The results of this study demonstrate that TC, 
TG, LDL-C and CRP significantly decreased after 
treatment in both groups, but the test group 
showed much lower values than control group 
after treatment; HDL-C of both groups increased 
significantly after treatment, but the test group 
exhibited higher values; IBS for AD of low echo 
plaque significantly improved in both groups, and 
again, the test group demonstrated greater 
improvement. 
 
Limitation of the study 
 
The sample size in this study was small. A larger 




Probucol in combination with atorvastatin is more 
effective in lowering TC, LDL-C and CRP level 
than atorvastatin. It regulates blood fat, resist 
oxidation and inflammation, improve vascular 
endothelial function, stabilize plaque, reverse 
plaque, and effectively restrain the occurrence 
and development of atherosclerotic lesion, 
Furthermore, The role of the combined therapy in 
preventing ischemic stroke significant. However, 
further studies are required to ascertain the full 
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